Canadian Bioceutical Subsidiary Wins 2014 CPG Editor's Choice Award For Best New Specialty Supplement for CinG-X(TM)
Back to Newsroom
Mentioned in this Article

Canadian Bioceutical Subsidiary Wins 2014 CPG Editor's Choice Award For Best New Specialty Supplement for CinG-X(TM)

Monday, January 5, 2015 9:00 AM
Share this article now

TORONTO, ONTARIO / ACCESSWIRE / January 5, 2015 / The Canadian Bioceutical Corporation ("BCC") (TSX VENTURE: BCC.V) 

CinG-X(TM), a patented nutritional supplement engineered for the promotion of healthy blood glucose levels, was named by the SupplySide editorial team as the Best Specialty Supplement/Food product at the SupplySide CPG Editor's Choice Awards Reception at the Mandalay Bay Resort in Las Vegas, Nevada in October.

CinG-X is a proprietary formulation containing highly-processed and concentrated cinnamon extracts and Panax Ginseng. The compound has a patented ratio which is designed to help maintain healthy blood sugar levels. Very specific dosages and ratios along with the mixture of ginsenosides (found in ginseng) and poly-phenols (found in cinnamon) are the basis for the patent. The ratio of these ingredients forms an effective combination that promotes healthy blood glucose levels, helping to improve cognitive function and an enhanced vitality of life.

High blood sugar is a deadly killer that relentlessly attacks the body. Over time, this action will significantly affect the cardio and neurological systems. CinG-X works by assisting the body in managing high blood sugar levels, a significant factor in the cause of diabetes, Alzheimer's and dementia. The CinG-X proprietary blend helps control the sugar metabolic process resulting in enhanced, physical cardiovascular, brain and neurological functions. 

CinG-X is licensed to CGX Life Sciences Inc., is sold in capsule form in the USA by the CinG-X Corporation of America and in Canada through the CinG-X Corporation and can be ordered online at All three companies are wholly-owned subsidiaries of The Canadian Bioceutical Corporation.

"We are delighted to have received this award", says Michael Arnkvarn, BCC's Chief Marketing Officer. "It is recognition by a committee of industry experts that CinG-X can be a valuable weapon in the battle being fought by the over 90 million people in North America plagued by high or unbalanced blood sugar levels."

To learn more about the other award winners, including product photos and short descriptions on their innovative positioning, in the SupplySide Editor's Choice Awards Winners Gallery, visit

About BCC

The Canadian Bioceutical Corporation is an Ontario corporation that develops and markets unique standardized mass-market and specialty nutraceutical and bioceutical products for the treatment and prevention of common ailments where present pharmaceutical treatments and over-the-counter (OTC) products fail to meet the needs of patients. BCC has targeted markets having clearly identified product deficiencies and dissatisfied consumers afflicted with a variety of medical conditions.

BCC obtains regulatory approval and patents for these unique compounds and formulations and may produce and distribute these products directly or license them for royalty revenues.

Through its recently acquired wholly-owned subsidiary, CGX Life Sciences Inc., BCC produces and distributes high quality nutraceuticals to provide safe, alternative treatments or to assist in the prevention of specific medical conditions, containing active ingredients formulated from natural herbal and botanical components.

CGX's principal brands are CinG-X(TM) and Relieva(TM).

For further information please contact:

Scott Boyes, President and CEO
[email protected]
(416) 223-6874

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Transaction and BCC's objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in BCC's public documents filed on SEDAR at; and other matters discussed in this news release. Although BCC believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, BCC disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the Policies of the Exchange) accepts responsibility of the adequacy or accuracy of this release.

 The Canadian Bioceutical Corporation

The Canadian Bioceutical Corporation
Back to Newsroom


Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions